| Identification | Back Directory | [Name]
BAY 299 | [CAS]
2080306-23-4 | [Synonyms]
BAY 299
CPD1617
BAY-299; BAY 299; BAY299
6-(3-hydroxypropyl)-2-(1,3,6-trimethyl-2-oxobenzimidazol-5-yl)benzo[de]isoquinoline-1,3-dione
6-(3-Hydroxy-propyl)-2-(1,3,6-trimethyl-2-oxo-2,3-dihydro-1H-benzoimidazol-5-yl)-benzo[de]isoquinoline-1,3-dione
6-(3-Hydroxypropyl)-2-(1,3,6-trimethyl-2-oxo-2,3-dihydro-1H-benzimidazol-5-yl)-1H-benzo[de]isoquinoline-1,3(2H)-dione
1H-Benz[de]isoquinoline-1,3(2H)-dione, 2-(2,3-dihydro-1,3,6-trimethyl-2-oxo-1H-benzimidazol-5-yl)-6-(3-hydroxypropyl)- | [Molecular Formula]
C25H23N3O4 | [MDL Number]
MFCD30480933 | [MOL File]
2080306-23-4.mol | [Molecular Weight]
429.47 |
| Chemical Properties | Back Directory | [Boiling point ]
688.7±55.0 °C(Predicted) | [density ]
1.377±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO:30.0(Max Conc. mg/mL);69.85(Max Conc. mM)
DMF:30.0(Max Conc. mg/mL);69.85(Max Conc. mM) | [form ]
A crystalline solid | [pka]
14.98±0.10(Predicted) | [color ]
Light yellow to yellow |
| Hazard Information | Back Directory | [Description]
BAY-299 is a potent and selective inhibitor of the bromodomain and PHD finger-containing (BRPF) family protein BRD1 (IC50 = 6 nM), also known as BRPF2, and the second bromodomain of transcription initiation factor TFIID subunits 1 (TAF1; IC50 = 13 nM). BAY-299 is >30-fold selective over BRPF1, BRPF3, BRD9, and ATAD2 and is >300-fold selective over BRD4. See the Structural Genomics Consortium (SGC) website for more information. | [Uses]
BAY 299, is a potent and selective inhibitor of the bromodomain and PHD finger-containing (BRPF) family protein BRD1, also known as BRPF2, and a strong inhibitor of TAF1/TAF1L BD2. These proteins play important roles in transcription regulation. | [in vivo]
Studies of the in vivo pharmacokinetic properties of BAY-299 in rat reveal that blood clearance is low (ca. 17% of hepatic blood flow), volume of distribution in steady-state high, terminal half-life long to very long (t1/2=10 h), and bioavailability high (F=73%). In vivo blood clearance is as anticipated based on rat liver microsome values but lower than expected based on hepatocyte data[1]. | [IC 50]
BRPF2 BD: 67 nM (IC50); BRPF1 BD: 3150 nM (IC50); BRPF3 BD: 5550 nM (IC50); TAF1 BD2: 8 nM (IC50); TAF1L BD2: 106 nM (IC50) | [storage]
Store at -20°C | [References]
[1] MONTSERRAT PéREZ-SALVIA M E. Bromodomain inhibitors and cancer therapy: From structures to applications[J]. Epigenetics, 2016, 12 1: 323-339. DOI: 10.1080/15592294.2016.1265710 |
|
|